Incidences of malignant neoplasms were low and stable with long-term ixekizumab treatment for people with psoriatic disease ...

Patients with psoriatic arthritis who meet clinical criteria for minimal disease activity also tend to report good disease ...

Significant gaps in arthritis subtype awareness among US adults underscore the need for improved health literacy and more ...

Metabolic syndrome is common in psoriatic arthritis and is a known risk factor for worse symptoms and poor treatment outcomes ...

When psoriatic arthritis symptoms are under control, you may be tempted to stop taking medication. Here’s why that’s a bad idea.

Racial and ethnic diversity is lacking in PsA clinical trials, with non-White participants remaining severely underrepresented.

Michaela Hagenhofer, General Manager, Commercial Operations at Johnson & Johnson Innovative Medicine, explains how J&J is ...

It is indicated for various diseases including heumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic ...

PsA can be challenging, but these expert-approved tips for reframing how you think, talk, and feel about your condition can ...

Zentiva Group has entered into a licence and supply agreement with pharmaceutical company Lupin for the commercialisation of ...

Lupin and Zentiva partner to commercialize Certolizumab Pegol biosimilar globally, sharing profits and investing in ...

What’s the prognosis for people with psoriatic arthritis? Can it affect your life expectancy or your quality of life? Find out what the research says.